ATE365742T1 - 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren - Google Patents

4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren

Info

Publication number: ATE365742T1
Authority: AT; Austria
Prior art keywords: aminothieno; pyrimidine; pde7 inhibitors; carbonitrile derivative; pde7
Prior art date: 2003-01-23

Application number

AT04704579T

Other languages

English (en)

Inventor

Belart Emma Terricabras

Matamoros Victor Segarra

Gomez Julio Alvarez-Builla

Lopez Juan Vaquero

Ortega Jose Minguez

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-23

Filing date

2004-01-23

Publication date

2007-07-15

2004-01-23 Application filed by Almirall Lab filed Critical Almirall Lab

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365742T1 publication Critical patent/ATE365742T1/de

Links

MLXWQNSUOXNSER-UHFFFAOYSA-N 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile Chemical class NC1=NC=NC2=C1C=C(C#N)S2 MLXWQNSUOXNSER-UHFFFAOYSA-N 0.000 title abstract 2
229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 title 1
239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Transplantation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04704579T 2003-01-23 2004-01-23 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren ATE365742T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200300172A ES2217956B1 (es)	2003-01-23	2003-01-23	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Publications (1)

Publication Number	Publication Date
ATE365742T1 true ATE365742T1 (de)	2007-07-15

Family

ID=32749101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04704579T ATE365742T1 (de)	2003-01-23	2004-01-23	4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren

Country Status (8)

Country	Link
US (1)	US7662814B2 (de)
EP (1)	EP1590352B1 (de)
JP (1)	JP2006515604A (de)
CN (1)	CN100582112C (de)
AT (1)	ATE365742T1 (de)
DE (1)	DE602004007239T2 (de)
ES (2)	ES2217956B1 (de)
WO (1)	WO2004065391A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4895806B2 (ja) *	2003-04-09	2012-03-14	エクセリクシス，インク．	Ｔｉｅ−２モジュレータと使用方法
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US7557112B2 (en) *	2004-10-08	2009-07-07	Astellas Pharma Inc.	Aromatic-ring-fused pyrimidine derivative
TW200621257A (en) *	2004-10-20	2006-07-01	Astellas Pharma Inc	Pyrimidine derivative fused with nonaromatic ring
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
JP2009532375A (ja) *	2006-03-30	2009-09-10	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
WO2007129161A2 (en)	2006-04-26	2007-11-15	F. Hoffmann-La Roche Ag	Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
TW200801012A (en)	2006-04-26	2008-01-01	Piramed Ltd	Phosphoinositide 3-kinase inhibitor compounds and methods of use
TWI498332B (zh)	2006-04-26	2015-09-01	Hoffmann La Roche	作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
GB0608820D0 (en) *	2006-05-04	2006-06-14	Piramed Ltd	Pharmaceutical compounds
WO2007146284A2 (en) *	2006-06-12	2007-12-21	Vertex Pharmaceuticals Incorporated	Thienopyrimidines useful as modulators of ion channels
RU2470936C2 (ru) *	2006-12-07	2012-12-27	Дженентек, Инк.	Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
MX2009005950A (es) *	2006-12-07	2009-10-12	Genentech Inc	Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
JP5580192B2 (ja) *	2007-03-27	2014-08-27	オメロスコーポレーション	運動障害の処置のためのｐｄｅ７インヒビターの使用
US8637528B2 (en) *	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
EP2205242B1 (de) *	2007-09-12	2015-04-15	Genentech, Inc.	Kombinationen von phosphoinositid-3-kinase-inhibitor-verbindungen und chemotherapeutischen mitteln und anwendungsverfahren
CA2704711C (en) *	2007-09-24	2016-07-05	Genentech, Inc.	Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP5348725B2 (ja) *	2007-10-25	2013-11-20	ジェネンテック，インコーポレイテッド	チエノピリミジン化合物の製造方法
GB0721095D0 (en)	2007-10-26	2007-12-05	Piramed Ltd	Pharmaceutical compounds
US20100093702A1 (en) *	2008-10-13	2010-04-15	Barbay J Kent	METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093714A1 (en) *	2008-10-13	2010-04-15	Devraj Chakravarty	AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2010103130A2 (en) *	2009-03-13	2010-09-16	Katholieke Universiteit Leuven, K.U.Leuven R&D	Novel bicyclic heterocycles
BRPI1009022A2 (pt) *	2009-05-27	2016-03-08	Hoffmann La Roche	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US8158625B2 (en) *	2009-05-27	2012-04-17	Genentech, Inc.	Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
EP2595993B1 (de)	2010-07-23	2018-04-18	President and Fellows of Harvard College	Trizyklische proteasomaktivitätsverstärkende verbindungen
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN106038567A (zh)	2010-11-08	2016-10-26	奥默罗斯公司	使用pde7抑制剂治疗成瘾和冲动控制障碍
AR090037A1 (es)	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
WO2013078126A1 (en)	2011-11-23	2013-05-30	Cancer Research Technology Limited	Thienopyrimidine inhibitors of atypical protein kinase c
EP2806875B1 (de)	2012-01-25	2017-07-19	Proteostasis Therapeutics, Inc.	Verbindungen zur modulierung einer proteasomaktivität
AU2013202373B2 (en) *	2012-01-25	2016-04-14	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
PL2900675T3 (pl) *	2012-09-28	2019-08-30	Takeda Pharmaceutical Company Limited	Sposób wytwarzania pochodnej tienopirymidyny
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3324974B1 (de) *	2015-07-24	2022-06-08	University Of Louisville Research Foundation, Inc.	Verbindungen, zusammensetzungen, verfahren zur behandlung von erkrankungen und verfahren zur zubereitung von verbindungen
JP2022551316A (ja)	2019-10-10	2022-12-08	ミオバントサイエンシズゲーエムベーハー	Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN115232146A (zh) *	2022-08-04	2022-10-25	山东大学	一种2-氨基噻吩并[2,3-d]嘧啶类化合物及其制备方法和应用
US20260048059A1 (en)	2022-08-18	2026-02-19	Klaus Wirth	Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4008726A1 (de) *	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
US5869486A (en) *	1995-02-24	1999-02-09	Ono Pharmaceutical Co., Ltd.	Fused pyrimidines and pyriazines as pharmaceutical compounds
JPH1087492A (ja) *	1996-06-25	1998-04-07	Ono Pharmaceut Co Ltd	一酸化窒素産生阻害剤
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
DE19953024A1 (de) *	1999-11-04	2001-05-10	Merck Patent Gmbh	Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19954707A1 (de) *	1999-11-13	2001-05-17	Merck Patent Gmbh	Imidazolverbindungen als Phosphodiesterase VII-Hemmer
CA2423981A1 (en) *	2000-09-29	2003-03-28	Kimiko Ichikawa	Thienopyrimidine compounds and salts thereof and process for the preparation of the same
EP1193261A1 (de) *	2000-10-02	2002-04-03	Warner-Lambert Company	Thiadiazole und ihre Verwendung als Phosphodiesterase-7 Inhibitoren
MXPA03009925A (es) *	2001-04-30	2004-06-30	Bayer Pharmaceuticals Corp	Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
EP1348701A1 (de) *	2002-03-28	2003-10-01	Warner-Lambert Company LLC	2,4-disubstituierte Thiazol-5-yl-Amine als PDE7-Inhibitoren

2003
- 2003-01-23 ES ES200300172A patent/ES2217956B1/es not_active Expired - Fee Related
2004
- 2004-01-23 AT AT04704579T patent/ATE365742T1/de not_active IP Right Cessation
- 2004-01-23 ES ES04704579T patent/ES2289475T3/es not_active Expired - Lifetime
- 2004-01-23 CN CN200480007362A patent/CN100582112C/zh not_active Expired - Fee Related
- 2004-01-23 US US10/542,940 patent/US7662814B2/en not_active Expired - Fee Related
- 2004-01-23 EP EP04704579A patent/EP1590352B1/de not_active Expired - Lifetime
- 2004-01-23 DE DE602004007239T patent/DE602004007239T2/de not_active Expired - Lifetime
- 2004-01-23 WO PCT/EP2004/000584 patent/WO2004065391A1/en not_active Ceased
- 2004-01-23 JP JP2006500010A patent/JP2006515604A/ja active Pending

Also Published As

Publication number	Publication date
US20060229306A1 (en)	2006-10-12
DE602004007239D1 (de)	2007-08-09
EP1590352B1 (de)	2007-06-27
CN100582112C (zh)	2010-01-20
JP2006515604A (ja)	2006-06-01
CN1761671A (zh)	2006-04-19
WO2004065391A1 (en)	2004-08-05
DE602004007239T2 (de)	2008-02-28
ES2217956B1 (es)	2006-04-01
ES2289475T3 (es)	2008-02-01
US7662814B2 (en)	2010-02-16
ES2217956A1 (es)	2004-11-01
EP1590352A1 (de)	2005-11-02

Legal Events

Date	Code	Title	Description
2007-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE365742T1 (de)	2007-07-15	4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
DK1678166T3 (da)	2009-11-09	Proteinkinaseinhibitorer
MXPA05010958A (es)	2006-01-30	Derivados indazol como inhibidores jnk.
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
GB0112348D0 (en)	2001-07-11	Compounds
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SG151260A1 (en)	2009-04-30	5-substituted-2-phenylamino-benzamides as mek inhibitors
WO2001064639A3 (en)	2002-02-28	Pde iv inhibiting amides, compositions and pharmaceutical use
ATE517882T1 (de)	2011-08-15	Chinolinderivate
NO20056030L (no)	2006-02-15	Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
NO20070837L (no)	2007-04-16	Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MX2010006748A (es)	2010-08-18	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
EA200600811A1 (ru)	2006-10-27	НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
PT828728E (pt)	2003-06-30	Di-hidrobenzofuranos de fenilo
PL1682528T3 (pl)	2008-01-31	Pochodne benzo[b][1,4]dioksepiny
CY1109366T1 (el)	2014-07-02	Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
IL175875A0 (en)	2006-10-05	Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
WO2006116733A3 (en)	2006-12-14	Protein kinase inhibitors
TW200745136A (en)	2007-12-16	4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
NO20063768L (no)	2006-11-02	1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer
ATE518858T1 (de)	2011-08-15	Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
MX2007001267A (es)	2007-07-11	Derivados de naftiridinas 2,8-disustituidas.
WO2004108094A3 (en)	2006-10-05	Sulfonamide-substituted chalcone derivatives and their use to treat diseases
ATE466013T1 (de)	2010-05-15	Pyrroloä3,2-cüpyridinderivate und verfahren zu deren herstellung